

**STATEMENT UNDER 37 CFR 3.73(b)**Applicant/Patent Owner: Elizabeth M. Denholm, Yong-Qing Lin, Paul J. SilverApplication No./Patent No.: 10/623,383 Filed/Issue Date: 07/18/2003Entitled: Attenuation of Tumor Growth, Metastasis, and AngiogenesisBioMarin Pharmaceutical Inc., a corporation of the State of Delaware

(Name of Assignee)

(Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

1. ☒ the assignee of the entire right, title, and interest; or
2. ☐ an assignee of less than the entire right, title and interest.  
The extent (by percentage) of its ownership interest is \_\_\_\_\_ %

in the patent application/patent identified above by virtue of either:

A ☐ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel \_\_\_\_\_, Frame \_\_\_\_\_, or for which a copy thereof is attached.


OR

B ☒ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:

Elizabeth M. Denholm, Yong-Qing1. From: Lin, Paul J. Silver To: Ibex Pharmaceuticals Inc.The document was recorded in the United States Patent and Trademark Office at  
Reel 017454, Frame 0289, or for which a copy thereof is attached.2. From: Ibex Pharmaceuticals Inc. To: BioMarin Enzymes, Inc.The document was recorded in the United States Patent and Trademark Office at  
Reel 017455, Frame 0238, or for which a copy thereof is attached.3. From: BioMarin Enzymes, Inc. To: BioMarin Pharmaceutical Inc.The document was recorded in the United States Patent and Trademark Office at  
Reel 017125, Frame 0248, or for which a copy thereof is attached.☐ Additional documents in the chain of title are listed on a supplemental sheet.☐ Copies of assignments or other documents in the chain of title are attached.

[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.



Signature

G. Eric Davis, Esq.

Printed or Typed Name

VP, Corporate Counsel

Title

March 28, 2006

Date

415-506-6307

Telephone Number

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 422 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.